Ménétrier disease is a rare disorder of the stomach in which the inner lining grows dramatically thicker, producing giant folds of tissue that leak protein into the gut and ultimately out of the body. The hallmark features are oversized gastric folds concentrated in the upper and middle portions of the stomach, excessive mucus production, and a steady loss of protein that drives down blood albumin levels and causes swelling in the limbs. Because it is so uncommon, many gastroenterologists will encounter only a handful of cases in an entire career, and the disease is frequently mistaken for other conditions that produce thickened stomach folds.
What Happens Inside the Stomach
In a healthy stomach, the inner lining has a carefully balanced mix of cell types: mucus-secreting cells near the surface, acid-producing parietal cells deeper down, and glands that release digestive enzymes. In Ménétrier disease, this balance tips heavily toward the mucus-producing surface cells. The surface pits elongate and multiply in a process called foveolar hyperplasia, while the deeper acid-producing glands shrink and waste away. The result is a stomach wall that is thick, rubbery, and thrown into enormous folds, sometimes several centimeters tall, that are visible on imaging and dramatic on endoscopy. These changes center on the fundus and body of the stomach, the upper two-thirds, while the antrum near the exit is relatively spared.1PubMed. Ménétrier’s disease: a narrative review of molecular pathogenesis, clinical spectrum and evolving therapeutic strategies
The thickened, overgrown mucosa becomes abnormally permeable. Protein from the bloodstream seeps through the stomach wall into the gut lumen, where it is digested and lost. This protein-losing gastropathy is what makes Ménétrier disease more than a cosmetic oddity of the stomach lining. As albumin levels fall, fluid that albumin normally holds in the bloodstream leaks into surrounding tissues, producing the peripheral edema (puffy ankles and legs, sometimes more widespread swelling) that often brings patients to the doctor in the first place.2PubMed Central. Ménétrier disease: A clinical review
The Molecular Driver
The overgrowth of surface cells in Ménétrier disease is not random. Research over the past three decades has traced it largely to excessive signaling through the epidermal growth factor receptor, a protein on cell surfaces that tells cells to grow and divide. In Ménétrier disease, the stomach lining overproduces a molecule called transforming growth factor alpha (TGF-α) that activates this receptor far more aggressively than normal.3PubMed Central. Ménétrier’s Disease: Its Mimickers and Pathogenesis
Some of the earliest evidence came from studying stomach tissue from patients alongside experiments in mice engineered to overproduce TGF-α. The human tissue showed intense TGF-α staining concentrated in mucous cells rather than in the parietal cells where it normally appears, while the transgenic mice developed features strikingly similar to the human disease: enlarged surface pits, cystic glands, increased mucus, and reduced acid secretion.4Gastroenterology. Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier’s disease: Supportive evidence from humans and transgenic mice This connection is more than academic. It opened the door to a targeted treatment, discussed further below, that blocks the receptor directly.
Symptoms and How They Progress
Ménétrier disease usually develops gradually in adults, and symptoms can be vague enough to delay diagnosis for months or years. The most common complaints are upper abdominal pain, nausea, vomiting, loss of appetite, and unintentional weight loss.5PubMed Central. Ménétrier disease: A clinical review Many patients also notice that their stomach feels full after eating only a small amount, because the thickened folds reduce the stomach’s effective capacity.
Swelling in the legs and feet, and sometimes around the eyes or in the abdomen, develops as protein loss progresses. In severe cases the albumin level drops low enough to cause serious complications: blood clots become more likely because the liver ramps up production of clotting proteins to compensate for the albumin loss, and the immune system may weaken as immunoglobulins are also lost through the leaky stomach lining. Acid secretion typically falls, since the acid-producing glands are replaced by mucous cells. Some patients produce so much thick mucus that it is visible as a heavy coating during endoscopy.
Diagnosing Ménétrier Disease
The diagnosis starts with upper endoscopy, which reveals the characteristic giant rugal folds in the body and fundus of the stomach, with thick mucus and sometimes surface erosions. The antrum tends to look relatively normal. But visual appearance alone is not enough, because several other conditions produce similar-looking large folds.
A critical step is obtaining the right kind of biopsy. Standard pinch biopsies taken during a routine endoscopy sample only the very surface of the mucosa. Because the diagnostic changes in Ménétrier disease extend deep into the full thickness of the mucosa, including the elongated pits and the atrophied glands below them, superficial samples often miss the picture entirely. Deep snare biopsies that capture the full mucosal thickness are necessary to evaluate the architecture properly and confirm the diagnosis.6Clinical Endoscopy. Chronic Ménétrier disease leading to gastric cancer in youth
Blood tests support the diagnosis but do not confirm it on their own. Low serum albumin in the setting of giant gastric folds is suggestive. Some clinicians measure fecal alpha-1 antitrypsin clearance, a test that quantifies how much protein is leaking through the gut wall, to document the protein-losing gastropathy objectively.
Conditions That Mimic the Disease
Several other stomach disorders can produce enlarged folds and lead to a misdiagnosis. Getting the distinction right matters because the treatments and prognoses are very different.
Zollinger-Ellison syndrome, caused by a gastrin-secreting tumor in the pancreas or duodenum, can thicken the stomach wall, but it does so by driving an overgrowth of acid-producing parietal cells rather than mucous cells. Under the microscope, Ménétrier disease shows marked parietal cell loss, the opposite of what Zollinger-Ellison produces. Patients with Zollinger-Ellison also tend to have stomach or duodenal ulcers and very high gastric acid output, neither of which is characteristic of Ménétrier disease.7PubMed Central. Distinguishing Ménétrier’s Disease from its Mimics
Gastric lymphoma and linitis plastica, a diffuse form of stomach cancer, can also produce thickened folds, as can certain infiltrative diseases. Helicobacter pylori infection occasionally causes large folds that can be confused with Ménétrier disease. Careful histological examination of deep biopsies, combined with the clinical picture and lab results, is what separates true Ménétrier disease from these lookalikes.
A Different Story in Children
When Ménétrier disease appears in children, it behaves quite differently from the adult form. Pediatric cases typically present suddenly, often with dramatic swelling and abdominal symptoms, but the disease is self-limiting in most children and resolves on its own within weeks to months.8PubMed Central. Diagnosis and Management of Ménétrier Disease in Children: A Case Series Review
The reason for this benign course appears to be tied to the cause. Pediatric Ménétrier disease has been linked to viral infections, most frequently cytomegalovirus (CMV), as well as Helicobacter pylori, herpes simplex virus, and Mycoplasma infections.9Clinical Endoscopy. Ménétrier’s Disease as a Gastrointestinal Manifestation of Active Cytomegalovirus Infection in a 22-Month-Old Boy CMV is the most commonly implicated trigger, and the disease remits as the infection clears.10PubMed. Menetrier disease and Cytomegalovirus infection in paediatric age: report of three cases and a review of the literature Detecting CMV can be tricky, though. Serology and PCR testing do not always agree, and some children who appear to have infection-driven disease test negative on one method while positive on another.11PubMed Central. Pediatric Ménétrier’s Disease Triggered by Cytomegalovirus Infection: A Rare Case of Severe Hypoalbuminemia and Edema
Other infectious triggers are less common but documented. At least one case in a child was traced to Clostridium difficile infection, and the child recovered after albumin support and treatment of the bacterial infection.12PubMed Central. Ménétrier’s disease in childhood: a case report from China In adults, by contrast, the disease is chronic rather than self-resolving, and a clear infectious trigger is rarely identified. This difference in natural history is one of the reasons some researchers consider pediatric Ménétrier disease a related but distinct entity from the adult form.
Treatment Options
Because Ménétrier disease is rare and tends to be chronic in adults, treatment has historically been difficult to study in large trials. Management strategies range from supportive care to targeted drugs to surgery, depending on severity.
Supportive and Symptomatic Care
For patients with mild protein loss and manageable symptoms, the initial approach focuses on maintaining nutrition and replacing lost protein. High-protein diets help compensate for enteral losses. Acid-suppressing medications, while they do not treat the underlying disease, can relieve some of the upper abdominal discomfort. Albumin infusions may be needed in severe episodes to keep serum albumin at safe levels and reduce edema.
Octreotide
Octreotide, a synthetic version of a hormone that slows secretion from many glands, has shown promise as a medical treatment. Published case series describe patients whose lab values normalized, whose stomach lining partially regressed, and whose symptoms improved after courses of octreotide lasting roughly three to fifteen months.13PubMed Central. Role of Octreotide in Menetrier’s Disease: Case Report and Review of Literature In one early report, subcutaneous octreotide rapidly resolved protein loss in a patient who had been on the verge of needing emergency stomach removal.14PubMed. Octreotide reduces enteral protein losses in Ménétrier’s disease The typical dosing involves either daily subcutaneous injections or a long-acting monthly injection. Octreotide is not a cure, and relapse after stopping the drug has been reported, but it can buy time and avoid or delay surgery.
Cetuximab
The discovery that overactive epidermal growth factor receptor signaling drives the disease led to a logical therapeutic experiment: block the receptor. Cetuximab, a monoclonal antibody originally developed for certain cancers, binds to the epidermal growth factor receptor and prevents it from being activated. A clinical study demonstrated that cetuximab could reduce the disease’s hallmark features, including the protein loss and the thickened gastric folds.15PubMed Central. Efficacy of cetuximab in the treatment of Menetrier’s disease This represents the most mechanism-targeted therapy available for the disease, though it requires intravenous infusions and is expensive. Cetuximab is not formally approved specifically for Ménétrier disease, so access can vary by institution and insurance coverage.
Surgery
When medications fail or when there is concern about cancer developing in the chronically abnormal stomach lining, surgical removal of the stomach becomes the definitive treatment. Although the disease primarily affects the upper stomach, total gastrectomy (removing the entire stomach) is generally preferred over partial removal. The reasoning is practical: total gastrectomy has been associated with better quality of life afterward and fewer surgical complications than partial procedures.16PubMed Central. Total gastrectomy for the treatment of Menetrier’s disease persistent to medical therapy: A case report Living without a stomach is manageable, though it requires permanent changes to eating habits, vitamin supplementation, and careful monitoring for nutritional deficiencies.
The Cancer Question
One of the most common concerns patients face after a Ménétrier disease diagnosis is whether the chronically abnormal stomach lining will turn cancerous. The association between the two has been discussed in the medical literature for decades, but the actual risk has been surprisingly hard to pin down because the disease is so rare.
In the largest study to examine this directly, gastric cancer developed in about 9% of patients with Ménétrier disease over a ten-year period after diagnosis, compared to roughly 4% in matched controls, though the difference did not reach statistical significance.17PubMed. Survival Times of Patients With Menetrier’s Disease and Risk of Gastric Cancer Earlier literature reviews have found that out of nearly 200 reported cases, fewer than 15 were associated with gastric adenocarcinoma.18PubMed Central. Early gastric cancer in Menetrier’s disease
So the risk appears to be elevated compared to the general population, but it is not so high that cancer is an inevitable outcome. Most gastroenterologists recommend regular endoscopic surveillance with deep biopsies to watch for precancerous changes. How often to scope varies by clinician and by how aggressive the disease appears, but annual or biennial surveillance is a common approach. The possibility of cancer is also one of the factors that tips the scale toward gastrectomy in patients whose disease is progressing despite medical treatment.
Why Diagnosis Often Takes So Long
Ménétrier disease is one of those conditions where the delay between first symptoms and correct diagnosis can stretch for years. There are several reasons for this. The early symptoms (vague upper abdominal pain, nausea, feeling full quickly) overlap with much more common problems like gastritis, peptic ulcer disease, and functional dyspepsia. A patient might receive acid-suppressing medication and feel somewhat better without anyone investigating further.
Even when endoscopy is performed, the diagnosis can be missed if the endoscopist takes only standard pinch biopsies. As noted above, superficial samples may show only the foveolar hyperplasia at the surface without revealing the glandular atrophy deeper down, leading to an incomplete or incorrect diagnosis. Radiologists seeing thickened folds on CT scans may raise the possibility of lymphoma or cancer first, since those are more common causes of a similar appearance. The rarity of the disease means it simply does not come to mind quickly for many clinicians.
For patients who are experiencing unexplained swelling along with stomach symptoms, especially if blood tests show low albumin without an obvious cause like liver or kidney disease, Ménétrier disease deserves a place on the differential diagnosis. Pushing for deep biopsies during endoscopy is the single most useful step toward getting a definitive answer.
Living with a Rare Gastric Disorder
Because Ménétrier disease affects so few people, patients often find themselves educating their own primary care providers about the condition. Support communities are small and scattered, and clinical trials are uncommon. The practical reality of living with the disease in its chronic adult form involves regular blood draws to monitor albumin and other protein levels, periodic endoscopies to watch for progression, and dietary adjustments to maximize protein intake.
Some patients go through periods of relative stability where their albumin holds steady and symptoms are mild, interspersed with flares where protein loss accelerates and swelling worsens. Flares may be triggered by infections, dietary changes, or no identifiable cause. During bad stretches, patients sometimes need intravenous albumin infusions, which typically require a visit to an infusion center or emergency department.
The psychological burden is worth acknowledging. Chronic fatigue from protein loss, unpredictable flares, the knowledge that cancer surveillance is necessary, and the possibility that surgery might eventually be unavoidable all weigh on patients. Because the disease is so uncommon, finding a gastroenterologist with specific experience can mean traveling to an academic medical center. Patients in rural areas or regions without a major teaching hospital face an added logistical layer on top of the disease itself.
Nutritional counseling from a dietitian familiar with protein-losing gastropathies can make a meaningful difference. Strategies include eating frequent smaller meals rather than three large ones, emphasizing easily digestible protein sources, and sometimes using medium-chain triglyceride supplements, which are absorbed differently than regular dietary fats and may help reduce protein losses in some patients. These measures do not treat the underlying disease but can improve day-to-day well-being and keep albumin levels from falling as steeply between medical interventions.